Abstract
Invasive aspergillosis is a serious problem for immunocompromised patients, especially if neutropenic. The diagnosis of this infection is complicated, since clinical symptoms are often similar to those of other fungal diseases. The chance of detecting the presence of a specific antigen in the serum could confirm the suspected clinical diagnosis and, perhaps, be useful for the follow-up of the patient. The Medical Mycology Committee of the Associazione Microbiologi Clinici Italiani (AMCLI) decided to evaluate in a multicenter prospective study (from 1 November 1998 to 28 February 1999) the performance of the Platelia® Aspergillus Kit (Bio-Rad) for the detection of Aspergillus galactomannan in human serum. The enrolled patients included various groups of immunosuppressed patients (mostly neutropenic). Blood samples were drawn at the time of enrollment. This decision was based upon a clinical diagnosis of probable aspergillosis (antibiotic non-responsive fever for at least 96 hours, cough, hemophthosis and positive chest X-ray). Additional blood samples were drawn on days 3, 6, 9, 12, 15 and 21. Culture and histopathologic examinations were performed according to the individual laboratory workflow. For each patient the laboratory filled a form with all the available clinical information, to create a database on which to evaluate the results of the test. During the study, 187 patients with various kinds of immunosuppression were enrolled. A total of 256 sera were tested: for 117 patients (62.6%) only the basal sample was tested, whereas for the 70 symptomatic patients (37.4%) multiple specimens (range: 1–6) were tested. The results allowed the laboratories to exclude (68.6%) or confirm (31.5%: confirmed and/or probable) the clinical diagnosis of invasive aspergillosis; 4 cases remained undetermined. Based on the results of this study, it seems that the use of this test should be limited to those patients with clinical symptoms of aspergillosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Denning DW and Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis 1990; 12: 1147–1201.
Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608–615.
Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarch A, Glotz D. Invasive aspergillosis after transplantation. Transplant Proc 1995; 27: 1307–1309.
Piens MA, Troncy J, Nicolle M.C, Mercatello A, Fière D, Mojon M. Aspergilloses invasives chez des patiens atteints d'hemopathies malignes. A propos de 29 observations. J Mycol Med 1993; 3: 79–83.
Singh N, Arnow PM, Bonham A, Dominguez E, Paterson DL, Pankey GE, Wagener MM, Yu VL. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716–720.
Toren A, Or R, Ackerstein A, Nagler A. Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation. Bone Marrow Transplant 1997; 20: 67–69.
Kac G, Roux P, Poirot JL, Meyohas MC, Cadranel J, Chouaid C, Watine J, Fourest F, Lancaster F. Aspergillus et aspergilloses: Őtude rŐtrospective dans deux hŹpitaux parisiens. J Mycol Med 1995; 5: 75–85.
Lebeau B, Piens MA, Kures L, Morin O, Pospisil F, Chevrier S, Cuisenier B, Gari-Toussaint M, De Gentile L, Raberin H, Lavarde V, Grillot R. Profil actuel de l'aspergillose invasive en France. EnquŘte du groupe des mycoses opportunists (GEMO) dans 19 centres hopitaliers (11 villes). J Mycol Med 1996; 6: 97–102.
Cohen J. Clinical manifestations and management of aspergillosis in the compromised patients. In: Warnock DW, Richardson MD, eds. Fungal infections in immunocompromised patients. Chichester: John Wiley & Sons, 1991: 118–145.
Grillot R, Lebeau B, Ambroise-Thomas P. L'aspergillose invasive: conduite du diagnostic mycologique. Pathol Biol 1994; 42: 675–682.
Maertens J, Verhaegen J, Demuynck H, Brock P, Verhoef G, Vandenberghe P, Van Eldere J, Verbist L, Boogaerts M. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37(10): 3223–3228.
Amstrong D. Overview of invasive fungal infections and clinical presentation. In: Meunier F, ed. Invasive fungal infections in cancer patients. London: Ballière Tindall, 1995: 17–24.
Verweij PE, Dompeling EC, Donnelly JP, Schattemberg AVMB, Meis JFGM. Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection 1997; 25: 86–89.
Verweij PE, Rijs AJMM, DePauw BE, Meis JFGM. Prospects for the early diagnosis of invasive aspergillosis in the immunocompromised patient. Rev Med Microbiol 1996; 7: 105–113.
Francis P Lee JW, Hoffman A, Peter J, Francesconi A. Bacher J, Shelhamer J, Pizzo PA, Walsh TJ. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as marker of infection. J Infect Dis 1994; 169: 356–368.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lombardi, G., Farina, C., Andreoni, S. et al. Multicenter evaluation of an enzyme immunoassay (Platelia® Aspergillus) for the detection of Aspergillus antigen in serum. Mycopathologia 155, 129–133 (2002). https://doi.org/10.1023/A:1020416308399
Issue Date:
DOI: https://doi.org/10.1023/A:1020416308399